Switch to:
Also traded in: France, Germany, Italy, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.56
SNY's Cash-to-Debt is ranked lower than
72% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.09 vs. SNY: 0.56 )
Ranked among companies with meaningful Cash-to-Debt only.
SNY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.14  Med: 0.56 Max: 10.62
Current: 0.56
0.14
10.62
Equity-to-Asset 0.55
SNY's Equity-to-Asset is ranked lower than
62% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. SNY: 0.55 )
Ranked among companies with meaningful Equity-to-Asset only.
SNY' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.48  Med: 0.58 Max: 0.65
Current: 0.55
0.48
0.65
Interest Coverage 23.85
SNY's Interest Coverage is ranked lower than
63% of the 635 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 105.95 vs. SNY: 23.85 )
Ranked among companies with meaningful Interest Coverage only.
SNY' s Interest Coverage Range Over the Past 10 Years
Min: 7.88  Med: 15.48 Max: 23.85
Current: 23.85
7.88
23.85
Piotroski F-Score: 7
Altman Z-Score: 1.99
Beneish M-Score: -2.64
WACC vs ROIC
6.00%
7.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 18.83
SNY's Operating Margin % is ranked higher than
79% of the 744 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.42 vs. SNY: 18.83 )
Ranked among companies with meaningful Operating Margin % only.
SNY' s Operating Margin % Range Over the Past 10 Years
Min: 15.25  Med: 18.36 Max: 20.7
Current: 18.83
15.25
20.7
Net Margin % 13.57
SNY's Net Margin % is ranked higher than
75% of the 745 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.16 vs. SNY: 13.57 )
Ranked among companies with meaningful Net Margin % only.
SNY' s Net Margin % Range Over the Past 10 Years
Min: 11.88  Med: 13.66 Max: 18.02
Current: 13.57
11.88
18.02
ROE % 8.32
SNY's ROE % is ranked higher than
55% of the 768 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.86 vs. SNY: 8.32 )
Ranked among companies with meaningful ROE % only.
SNY' s ROE % Range Over the Past 10 Years
Min: 6.5  Med: 8.61 Max: 11.68
Current: 8.32
6.5
11.68
ROA % 4.62
SNY's ROA % is ranked higher than
56% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.49 vs. SNY: 4.62 )
Ranked among companies with meaningful ROA % only.
SNY' s ROA % Range Over the Past 10 Years
Min: 3.78  Med: 5.11 Max: 7.03
Current: 4.62
3.78
7.03
ROC (Joel Greenblatt) % 48.18
SNY's ROC (Joel Greenblatt) % is ranked higher than
83% of the 785 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.40 vs. SNY: 48.18 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
SNY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 31.14  Med: 42.95 Max: 63.82
Current: 48.18
31.14
63.82
3-Year Revenue Growth Rate 4.70
SNY's 3-Year Revenue Growth Rate is ranked lower than
55% of the 607 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.70 vs. SNY: 4.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
SNY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.5  Med: 6.3 Max: 27.4
Current: 4.7
-3.5
27.4
3-Year EBITDA Growth Rate -2.10
SNY's 3-Year EBITDA Growth Rate is ranked lower than
69% of the 583 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.40 vs. SNY: -2.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
SNY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 4.2 Max: 35.5
Current: -2.1
-7.1
35.5
3-Year EPS without NRI Growth Rate 7.70
SNY's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 551 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.00 vs. SNY: 7.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
SNY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -13.4  Med: 3.4 Max: 41.7
Current: 7.7
-13.4
41.7
» SNY's 10-Y Financials

Financials (Next Earnings Date: 2017-10-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

SNY Guru Trades in Q2 2016

Lee Ainslie 42,790 sh (New)
John Paulson 395,500 sh (New)
David Dreman 20,204 sh (+980.43%)
HOTCHKIS & WILEY 11,432,112 sh (+12.47%)
Manning & Napier Advisors, Inc 288,410 sh (+4.68%)
Dodge & Cox 55,155,913 sh (+3.04%)
Joel Greenblatt 35,571 sh (+2.45%)
Charles Brandes 3,600,731 sh (+1.24%)
John Buckingham 123,489 sh (+1.03%)
Ken Fisher 13,638,183 sh (+0.67%)
Sarah Ketterer 393,781 sh (+0.55%)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 27,697 sh (unchged)
Bill Nygren 5,470,000 sh (unchged)
NWQ Managers Sold Out
Paul Tudor Jones Sold Out
Barrow, Hanley, Mewhinney & Strauss 28,122,279 sh (-3.32%)
PRIMECAP Management 2,218,107 sh (-12.99%)
» More
Q3 2016

SNY Guru Trades in Q3 2016

NWQ Managers 335,521 sh (New)
Barrow, Hanley, Mewhinney & Strauss 31,320,327 sh (+11.37%)
Dodge & Cox 59,267,298 sh (+7.45%)
John Paulson 417,000 sh (+5.44%)
HOTCHKIS & WILEY 12,041,028 sh (+5.33%)
Sarah Ketterer 394,507 sh (+0.18%)
Francis Chou 410,000 sh (unchged)
David Dreman 20,204 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Murray Stahl 27,697 sh (unchged)
Lee Ainslie Sold Out
Charles Brandes 3,557,856 sh (-1.19%)
Manning & Napier Advisors, Inc 284,817 sh (-1.25%)
John Buckingham 120,078 sh (-2.76%)
Joel Greenblatt 32,879 sh (-7.57%)
PRIMECAP Management 2,037,207 sh (-8.16%)
Ken Fisher 12,443,197 sh (-8.76%)
Bill Nygren 3,170,000 sh (-42.05%)
» More
Q4 2016

SNY Guru Trades in Q4 2016

NWQ Managers 483,670 sh (+44.15%)
Dodge & Cox 68,508,540 sh (+15.59%)
Joel Greenblatt 33,032 sh (+0.47%)
Ken Fisher 12,492,035 sh (+0.39%)
PRIMECAP Management 2,037,207 sh (unchged)
Francis Chou 410,000 sh (unchged)
Warren Buffett 3,905,875 sh (unchged)
Bill Nygren 3,170,000 sh (unchged)
Murray Stahl 26,697 sh (-3.61%)
Charles Brandes 3,387,715 sh (-4.78%)
HOTCHKIS & WILEY 11,338,645 sh (-5.83%)
Barrow, Hanley, Mewhinney & Strauss 29,377,146 sh (-6.20%)
Sarah Ketterer 352,841 sh (-10.56%)
Manning & Napier Advisors, Inc 226,188 sh (-20.58%)
John Buckingham 93,371 sh (-22.24%)
John Paulson 253,000 sh (-39.33%)
David Dreman 1,030 sh (-94.90%)
» More
Q1 2017

SNY Guru Trades in Q1 2017

Manning & Napier Advisors, Inc 244,282 sh (+8.00%)
Ken Fisher 12,615,505 sh (+0.99%)
» More
» Details

Insider Trades

Latest Guru Trades with SNY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412    SIC: 2834
Compare:OTCPK:GLAXF, NYSE:ABBV, OTCPK:BAYZF, NYSE:LLY, NYSE:BMY, NYSE:AZN, NYSE:MRK, OTCPK:NVSEF, OTCPK:SZUKF, OTCPK:ALPMF, OTCPK:OTSKY, NYSE:PFE, OTCPK:CHGCY, OTCPK:DSNKY, OTCPK:OPHLY, OTCPK:RHHBY, OTCPK:KYKOF, OTCPK:PTKFY, OTCPK:SNPHF, OTCPK:GWPRF » details
Traded in other countries:SAN.France, SNW.Germany, SANF.Italy, SNYN.Mexico, SAN.Switzerland, 0O59.UK, SNYNF.USA,
Headquarter Location:France
Sanofi SA is a healthcare company engaged in the research, development, manufacture and marketing of healthcare products.

Sanofi develops and markets drugs with a concentration in oncology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing close to 15% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Guru Investment Theses on Sanofi SA

First Eagle Investments Comments on Sanofi - Oct 24, 2016

Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.



From First Eagle Global Value Fund third-quarter 2016 commentary.



Check out First Eagle Investment latest stock trades

Top Ranked Articles about Sanofi SA

First Eagle Investments Comments on Sanofi Guru stock highlight
Sanofi (NYSE:SNY) is a French pharmaceutical company that experienced softness in its diabetes business in the United States. The company’s US patent for Lantus, its primary insulin drug, expired in 2015, and competition from less expensive biosimilars weighted on Sano-fi’s share price. At the same time, Sanofi’s vaccines business and the specialty care areas its acquired in the purchase of Genzyme did well during the quarter.

Read more...
Sanofi Sues Merck Over Patent Infringement Company trying to prevent further competition, reverse declining sales
French pharmaceutical giant Sanofi SA (NYSE:SNY) filed a lawsuit against Merck & Co. (NYSE:MRK) for supposed patent infringements last Friday. Read more...
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap The deal will be accretive to EPS after 2017, so investors will have to wait
Of the top pharma companies with more than $100 billion valuation, Sanofi (NYSE:SNY) is one of the cheapest, trading at 21 times earnings and a lowly 12.3 times forward earnings. Revenue has been flat for the last three years while their stock price followed suit, staying put around the $70 level. Sales decline is yet to stop, with the company reporting a 0.2% decline during the second quarter - the primary reason behind such low valuation for the company. Read more...
Sanofi's Risk Increases on Acquisition Miss Is the stable dividend growth worth the investment risk?
French pharma giant Sanofi (NYSE:SNY) has been having a forgettable 2016, with stocks sliding by more than 18% in the last year. Net sales in the first six months of the current fiscal declined to 15.926 billion euro from 16.629 billion euro last year, sending the stock lower. The steady drop in the past year has brought the company’s dividend yield to an extremely attractive 4.2% yield. But how safe is the dividend? Read more...

Ratios

vs
industry
vs
history
PE Ratio 23.93
SNY's PE Ratio is ranked higher than
63% of the 556 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.48 vs. SNY: 23.93 )
Ranked among companies with meaningful PE Ratio only.
SNY' s PE Ratio Range Over the Past 10 Years
Min: 9.75  Med: 19.65 Max: 32.04
Current: 23.93
9.75
32.04
Forward PE Ratio 15.04
SNY's Forward PE Ratio is ranked higher than
69% of the 202 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.39 vs. SNY: 15.04 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 25.58
SNY's PE Ratio without NRI is ranked higher than
58% of the 544 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.85 vs. SNY: 25.58 )
Ranked among companies with meaningful PE Ratio without NRI only.
SNY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.04  Med: 19.65 Max: 32.67
Current: 25.58
10.04
32.67
Price-to-Owner-Earnings 16.71
SNY's Price-to-Owner-Earnings is ranked higher than
77% of the 293 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 33.45 vs. SNY: 16.71 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
SNY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.31  Med: 13.26 Max: 21.33
Current: 16.71
7.31
21.33
PB Ratio 1.94
SNY's PB Ratio is ranked higher than
69% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.03 vs. SNY: 1.94 )
Ranked among companies with meaningful PB Ratio only.
SNY' s PB Ratio Range Over the Past 10 Years
Min: 1.16  Med: 1.62 Max: 2.33
Current: 1.94
1.16
2.33
PS Ratio 3.22
SNY's PS Ratio is ranked lower than
52% of the 721 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. SNY: 3.22 )
Ranked among companies with meaningful PS Ratio only.
SNY' s PS Ratio Range Over the Past 10 Years
Min: 1.76  Med: 2.66 Max: 4.12
Current: 3.22
1.76
4.12
Price-to-Free-Cash-Flow 18.42
SNY's Price-to-Free-Cash-Flow is ranked higher than
63% of the 226 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.83 vs. SNY: 18.42 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
SNY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.49  Med: 14.78 Max: 21.14
Current: 18.42
7.49
21.14
Price-to-Operating-Cash-Flow 13.70
SNY's Price-to-Operating-Cash-Flow is ranked higher than
64% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.62 vs. SNY: 13.70 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
SNY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 6.08  Med: 10.47 Max: 17.15
Current: 13.7
6.08
17.15
EV-to-EBIT 20.24
SNY's EV-to-EBIT is ranked higher than
65% of the 776 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.99 vs. SNY: 20.24 )
Ranked among companies with meaningful EV-to-EBIT only.
SNY' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.1  Med: 16.6 Max: 24.6
Current: 20.24
9.1
24.6
EV-to-EBITDA 13.01
SNY's EV-to-EBITDA is ranked higher than
77% of the 797 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.26 vs. SNY: 13.01 )
Ranked among companies with meaningful EV-to-EBITDA only.
SNY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 8.4 Max: 15
Current: 13.01
5.1
15
Shiller PE Ratio 22.25
SNY's Shiller PE Ratio is ranked higher than
80% of the 161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.67 vs. SNY: 22.25 )
Ranked among companies with meaningful Shiller PE Ratio only.
SNY' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.6  Med: 19.77 Max: 27.36
Current: 22.25
14.6
27.36
Current Ratio 1.62
SNY's Current Ratio is ranked lower than
70% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.55 vs. SNY: 1.62 )
Ranked among companies with meaningful Current Ratio only.
SNY' s Current Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.65 Max: 2.71
Current: 1.62
0.79
2.71
Quick Ratio 1.20
SNY's Quick Ratio is ranked lower than
71% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.85 vs. SNY: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
SNY' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.23 Max: 2.41
Current: 1.2
0.59
2.41
Days Inventory 232.77
SNY's Days Inventory is ranked lower than
87% of the 689 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.29 vs. SNY: 232.77 )
Ranked among companies with meaningful Days Inventory only.
SNY' s Days Inventory Range Over the Past 10 Years
Min: 178.09  Med: 195.24 Max: 232.77
Current: 232.77
178.09
232.77
Days Sales Outstanding 76.88
SNY's Days Sales Outstanding is ranked lower than
51% of the 636 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 75.05 vs. SNY: 76.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
SNY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.29  Med: 76.54 Max: 83.73
Current: 76.88
61.29
83.73
Days Payable 146.55
SNY's Days Payable is ranked higher than
84% of the 586 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.53 vs. SNY: 146.55 )
Ranked among companies with meaningful Days Payable only.
SNY' s Days Payable Range Over the Past 10 Years
Min: 104.92  Med: 125.26 Max: 146.55
Current: 146.55
104.92
146.55

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.58
SNY's Dividend Yield % is ranked higher than
88% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.58 vs. SNY: 3.58 )
Ranked among companies with meaningful Dividend Yield % only.
SNY' s Dividend Yield % Range Over the Past 10 Years
Min: 2.46  Med: 3.76 Max: 5.24
Current: 3.58
2.46
5.24
Dividend Payout Ratio 0.86
SNY's Dividend Payout Ratio is ranked lower than
87% of the 410 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.35 vs. SNY: 0.86 )
Ranked among companies with meaningful Dividend Payout Ratio only.
SNY' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.46  Med: 0.72 Max: 1.02
Current: 0.86
0.46
1.02
3-Year Dividend Growth Rate 1.90
SNY's 3-Year Dividend Growth Rate is ranked lower than
66% of the 285 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. SNY: 1.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
SNY' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -15.6  Med: 7.8 Max: 37.9
Current: 1.9
-15.6
37.9
Forward Dividend Yield % 3.40
SNY's Forward Dividend Yield % is ranked higher than
85% of the 658 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.59 vs. SNY: 3.40 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.16
SNY's 5-Year Yield-on-Cost % is ranked higher than
81% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.09 vs. SNY: 4.16 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
SNY' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.85  Med: 4.36 Max: 6.07
Current: 4.16
2.85
6.07
3-Year Average Share Buyback Ratio 0.80
SNY's 3-Year Average Share Buyback Ratio is ranked higher than
90% of the 442 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.30 vs. SNY: 0.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SNY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -24.5  Med: -0.1 Max: 2.2
Current: 0.8
-24.5
2.2

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 17.59
SNY's Price-to-Tangible-Book is ranked lower than
91% of the 705 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.61 vs. SNY: 17.59 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
SNY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 7.22  Med: 14.99 Max: 41.94
Current: 17.59
7.22
41.94
Price-to-Intrinsic-Value-Projected-FCF 1.05
SNY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
85% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.56 vs. SNY: 1.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
SNY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.57  Med: 0.93 Max: 1.45
Current: 1.05
0.57
1.45
Price-to-Median-PS-Value 1.22
SNY's Price-to-Median-PS-Value is ranked lower than
52% of the 645 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.13 vs. SNY: 1.22 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
SNY' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.69  Med: 1.18 Max: 3.55
Current: 1.22
0.69
3.55
Price-to-Graham-Number 4.47
SNY's Price-to-Graham-Number is ranked lower than
80% of the 408 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. SNY: 4.47 )
Ranked among companies with meaningful Price-to-Graham-Number only.
SNY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.92  Med: 4.07 Max: 6.63
Current: 4.47
1.92
6.63
Earnings Yield (Greenblatt) % 4.94
SNY's Earnings Yield (Greenblatt) % is ranked higher than
74% of the 1046 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.36 vs. SNY: 4.94 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
SNY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.1  Med: 6 Max: 11
Current: 4.94
4.1
11
Forward Rate of Return (Yacktman) % 1.63
SNY's Forward Rate of Return (Yacktman) % is ranked lower than
66% of the 369 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.72 vs. SNY: 1.63 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
SNY' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 0.7  Med: 11 Max: 24
Current: 1.63
0.7
24

More Statistics

Revenue (TTM) (Mil) $37,728
EPS (TTM) $ 1.97
Beta0.76
Short Percentage of Float0.19%
52-Week Range $36.81 - 46.16
Shares Outstanding (Mil)2,584.04

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 39,325 40,970 43,513
EPS ($) 3.04 3.19 3.60
EPS without NRI ($) 3.04 3.19 3.60
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.68%
Dividends per Share ($) 1.62 1.73 1.85
» More Articles for SNY

Headlines

Articles On GuruFocus.com
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent® (aliro Apr 25 2017 
Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant Reject Apr 24 2017 
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients Apr 24 2017 
Can Pluristem Therapeutics Corner the Acute Radiation Syndrome Market? Apr 11 2017 
Sanofi Launches First-Ever ACT® Kids Toothpaste in the U.S. Apr 03 2017 
Switching to Sanofi's Toujeo® Showed Significant Reductions in Blood Sugar and Significantly Lower Apr 02 2017 
Award-Winning International Fund Manager David Herro Picks 3 Stocks Mar 03 2017 
While Big Diabetes Stagnates, Smaller Companies Are Moving Faster Than Ever Feb 09 2017 
David Herro's Oakmark International Fund Fourth Quarter Letter Jan 11 2017 

More From Other Websites
Why Flexion Therapeutics Inc. Stock Is Tanking Apr 26 2017
Moody's: Outlook for global pharmaceuticals industry stable on low earnings growth, new product... Apr 26 2017
K-Mart to Sell Cheaper EpiPen Alternative Apr 25 2017
New Data Suggest Positive Effects of Sanofi Genzyme’s Aubagio® (teriflunomide) on Cortical Gray... Apr 25 2017
Sanofi and Regeneron Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent®... Apr 25 2017
New Investigational Data on Six-Year Efficacy of Sanofi Genzyme’s Lemtrada® (alemtuzumab) in... Apr 25 2017
Regeneron and Sanofi Announce FDA Approval of a New Once-Monthly Dosing Option for Praluent®... Apr 25 2017
Mylan Tried to ‘Squelch’ EpiPen Rival, Sanofi Says in Lawsuit Apr 24 2017
Sanofi Sues Mylan Over EpiPen Practices Apr 24 2017
Sanofi files U.S. antitrust lawsuit against Mylan over EpiPen Apr 24 2017
Sanofi has filed an antitrust suit against Mylan alleging 'illegal conduct' to prevent EpiPen... Apr 24 2017
Sanofi Receives FDA Approval of Thymoglobulin® for the Prevention of Acute Kidney Transplant... Apr 24 2017
Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients... Apr 24 2017
[$$] Sanofi plays down need for pharma deals Apr 23 2017
Amgen Trumps Regeneron, Sanofi In Cholesterol Drug Sales Apr 21 2017
EMA panel recommends nod for Sanofi, Regeneron's arthritis drug Apr 21 2017
Regulator links Sanofi epilepsy drug to child deformities Apr 20 2017
[$$] Sanofi epilepsy drug caused birth defects in up to 4,100 children Apr 20 2017
Sanofi Epilepsy Drug Responsible for Birth Defects in 4,100 Children, French Regulator Says Apr 20 2017
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Apr 20 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)